Doctors that prescribe peptides
How does an online visit turn into a legitimate prescription? These articles walk through it: what happens in an intake, why doctors that prescribe peptides online must be licensed in your state, how compounding pharmacies fill orders, and what to expect from your first visit.
If you've only seen peptides sold with no questions asked, this topic explains what the doctor-in-the-loop model changes — including that not everyone qualifies. Every state is different, and the licensure article explains why that matters more than most people expect.
112 articles on this topic
-
FDA Peptide Policy: Under Review, Not in Effect Yet
The White House logged a new FDA peptide policy notice on October 14, 2026, but the text is not public yet. Here is what the official record confirms, what unnamed sources reported about BPC-157, and what stays the same today.
-
Tirzepatide Telehealth Study: 15.5% Loss at Six Months
A large UK digital program tracked 8,127 women starting treatment, almost all on tirzepatide. Women with six-month weigh-ins lost an average of 15.5% of their starting weight, though study limits matter.
-
Epitalon for Sleep: Better Sleep Isn't Established
Epitalon has been studied for melatonin production, but better sleep hasn't been demonstrated in people. The small human study measured a hormone marker.
-
Thymosin Alpha 1 Sepsis Trial: What TESTS Found
TESTS found no clear reduction in sepsis deaths: 23.4% with thymosin alpha-1 versus 24.1% with placebo. Its subgroup findings remain tentative.
-
CJC-1295 Ipamorelin News: October 2026
The quarter brought a new WADA list, online-product notices and an evidence review. The two molecules still have different FDA records and limited human outcome data.
-
10 Questions to Ask Before BPC-157
Ten questions explain what a BPC-157 visit needs to cover, from medical history and evidence limits to sport testing and follow-up.
-
Thymosin Alpha 1 News: October 2026 Update
New studies broaden the research questions, while U.S. status remains unchanged. Here is what the July–September quarter adds to a prescribing conversation.
-
Epitalon Telomeres: What the Studies Actually Show
The claim comes from cells studied outside the body. Those findings haven't established a longer or healthier life for people taking epitalon.
-
10 Questions to Ask Before PT-141
A PT-141 visit starts with fit and safety. These ten questions clarify the evidence, medical history, side effects, and follow-up plan.
-
Is Epitalon FDA Approved? It Is Not
Epitalon is not FDA-approved. Its July 2026 committee recommendation concerned a compounding ingredient list, and FDA has not completed that rulemaking.
-
SS-31 News: October 2026 Update
Forzinity's follow-up trial is underway. Fresh mouse and cell studies add research questions, while the label remains limited to Barth syndrome.
-
Who Discovered Thymosin Alpha 1? Goldstein’s Team
Goldstein, White and Slater reported thymosin in 1966. A larger team isolated alpha-1 in 1977, opening the path to synthetic thymalfasin and Zadaxin.
-
Semax News Update: October 2026
FDA’s advisory panel supported listing Semax for compounding in July. The published list and the limits of the human studies still matter.
-
10 Questions to Ask Before Starting Sermorelin
A sermorelin visit covers the goal, health history, labs, and a practical follow-up plan. These ten questions explain why each part matters and what a clear answer includes.
-
CJC-1295 FDA Status: Nominations, Review and Votes
CJC-1295 is not FDA-approved; a compounded prescription is different from an FDA-approved product. Here is what its nominations and votes mean today.
-
When Did the Tirzepatide Shortage End? The Dates
The FDA took tirzepatide off its shortage list on October 2, 2024. A lawsuit, a second decision and two grace periods followed. Here is the timeline, read from the FDA's own documents, and what it means for a prescription today.
-
Why Do People Stop Taking GLP-1? Cost Matters
A new semaglutide study links higher patient costs with poorer adherence. The recurring bill deserves a conversation before the first shipment.
-
GLP-1 Without Diabetes or Obesity: Use Is Rising
A September study found more than 1.1 million GLP-1 recipients without documented eligibility. It raises questions about screening and evidence, without judging every prescription.
-
13 Questions to Ask Before Tesamorelin
A tesamorelin review turns on a short list: what you want it for, your cancer, pregnancy and pituitary history, and your blood sugar and IGF-1. Here are the questions worth bringing, and the label line or trial finding behind each.
-
Should I Take BPC-157? How a Provider Decides
Should I take BPC-157? It may be worth discussing for a specific, examined problem, but a provider first checks the injury, the gut, drug testing, cancer history, pregnancy and your other medicines.
Page 1 of 6 · 112 articles